Hospital
Kaleida Health
Kaleida Health was paid $22.02M by Medicaid between Jan 2018 and Feb 2024, across 391 billing codes. Its largest line is G0378, Hospital observation service, per hour — 12% of everything it billed.
33Billing provider infoKALEIDA HEALTH
BUFFALO, NY 14203
BUFFALO, NY 14203
33aNPI1366473183assigned 07/06/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$22.02M
24GClaims423,241
24DCodes billed391
24AFirst – last monthJan 2018 – Feb 2024
Compared with peers
Next to other General Acute Care Hospital providers in New York
Rank by total paid#58 of 231
Median peer was paid$561K
This provider vs. median39×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 357 | $17K | |
| 2019 | 70,047 | $3.59M | |
| 2020 | 219,574 | $11.62M | |
| 2021 | 130,746 | $6.72M | |
| 2022 | 969 | $29K | |
| 2023 | 1,490 | $46K | |
| 2024incomplete | 58 | $3K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| G0378 | Hospital observation service, per hour | 12% | 1,729 | 1,674 | $2.60M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 8.7% | 14,815 | 13,945 | $1.92M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 7.7% | 16,295 | 13,868 | $1.69M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 5.1% | 9,746 | 9,174 | $1.12M |
| D2930 | Prefabricated stainless steel crown - primary tooth | 4.5% | 1,287 | 1,287 | $993K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 3.6% | 7,313 | 6,887 | $795K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 3.2% | 10,154 | 9,040 | $707K |
| 96361 | Intravenous infusion, hydration; each additional hour | 3.1% | 3,170 | 2,970 | $689K |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | 2.4% | 411 | 411 | $521K |
| 59025 | Fetal non-stress test | 2.1% | 2,889 | 1,893 | $472K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 2.1% | 4,468 | 4,260 | $452K |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | 1.9% | 354 | 354 | $415K |
379 more codes
| 70450 | Computed tomography, head or brain; without contrast material | 1.6% | 1,437 | $360K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.6% | 3,064 | $357K |
| 99203 | Doctor's office visit, new patient (routine) | 1.6% | 3,254 | $342K |
| 52000 | 1.5% | 251 | $341K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.5% | 454 | $327K |
| 80053 | Comprehensive metabolic panel | 1.4% | 16,708 | $312K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 1.2% | 8,459 | $259K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.2% | 921 | $259K |
| 99204 | Doctor's office visit, new patient (more involved) | 1.1% | 2,089 | $249K |
| 93975 | <1% | 533 | $216K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,315 | $210K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 1,635 | $205K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 1,803 | $190K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 2,114 | $180K |
| 96415 | <1% | 356 | $176K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 8,408 | $161K |
| D3220 | Therapeutic pulpotomy (excluding final restoration) - removal of pulp coronal to the dentinocemental junction | <1% | 808 | $161K |
| D7140 | Extraction, erupted tooth or exposed root | <1% | 436 | $140K |
| 90847 | Family psychotherapy with the patient present, 50 minutes | <1% | 777 | $137K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 1,238 | $135K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 1,940 | $135K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 505 | $129K |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 973 | $127K |
| 99442 | <1% | 1,151 | $127K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 6,765 | $127K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 524 | $123K |
| 76770 | <1% | 521 | $115K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 368 | $115K |
| 12001 | <1% | 271 | $107K | |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 863 | $104K |
| 42830 | <1% | 81 | $104K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,675 | $100K |
| Q5103 | Injection, infliximab-dyyb, biosimilar, (inflectra), 10 mg | <1% | 80 | $99K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 3,280 | $98K |
| 12011 | <1% | 259 | $97K | |
| 99205 | Prolong outpt/office vis | <1% | 856 | $94K |
| 96112 | <1% | 647 | $86K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 1,448 | $84K |
| 99443 | <1% | 752 | $83K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 333 | $78K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 144 | $75K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 497 | $75K |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 751 | $73K |
| 86900 | <1% | 2,146 | $68K | |
| D2390 | <1% | 292 | $68K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 405 | $64K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 1,013 | $63K |
| 99441 | <1% | 590 | $63K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 2,605 | $62K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 4,323 | $61K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,737 | $61K |
| 86901 | <1% | 2,153 | $60K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 859 | $59K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 781 | $56K |
| 95819 | <1% | 427 | $55K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 719 | $54K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 2,962 | $48K |
| 76000 | <1% | 379 | $45K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 1,715 | $44K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 3,511 | $41K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 5,016 | $40K |
| 76801 | <1% | 638 | $39K | |
| 76820 | <1% | 654 | $36K | |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 429 | $35K |
| 86850 | <1% | 2,143 | $35K | |
| D2391 | Resin-based composite - one surface, posterior, primary or permanent | <1% | 178 | $35K |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 311 | $33K |
| 88304 | <1% | 515 | $32K | |
| 76813 | <1% | 467 | $32K | |
| 51600 | <1% | 67 | $31K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 17,046 | $30K |
| 80061 | Lipid panel | <1% | 3,981 | $30K |
| 10060 | <1% | 100 | $30K | |
| D2330 | <1% | 174 | $27K | |
| 83655 | <1% | 1,783 | $27K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 4,066 | $26K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 6,556 | $25K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 170 | $25K |
| 90791 | Psychiatric diagnostic evaluation | <1% | 157 | $25K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 491 | $25K |
| 97161 | <1% | 363 | $24K | |
| 87631 | <1% | 470 | $22K | |
| 76821 | <1% | 491 | $22K | |
| 99385 | <1% | 191 | $22K | |
| 84153 | <1% | 1,058 | $22K | |
| 83880 | <1% | 744 | $21K | |
| 90833 | Psychotherapy, 30 minutes with patient when performed with an E&M service (add-on) | <1% | 400 | $21K |
| 81025 | <1% | 6,350 | $20K | |
| 70496 | <1% | 79 | $20K | |
| 76830 | Ultrasound, transvaginal | <1% | 400 | $19K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,979 | $19K |
| 84439 | <1% | 2,054 | $18K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 437 | $18K |
| 97162 | <1% | 182 | $18K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 224 | $18K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 162 | $17K |
| D1351 | Sealant - per tooth | <1% | 205 | $16K |
| 85008 | <1% | 1,661 | $16K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 531 | $15K |
| 36415 | Collection of venous blood by venipuncture | <1% | 14,561 | $15K |
| 92567 | <1% | 706 | $14K | |
| 74455 | <1% | 67 | $14K | |
| 70486 | <1% | 135 | $13K | |
| 86780 | <1% | 3,022 | $13K | |
| 84403 | <1% | 531 | $13K | |
| 76818 | <1% | 175 | $12K | |
| D2392 | Resin-based composite - two surfaces, posterior, primary or permanent | <1% | 64 | $12K |
| 90715 | <1% | 423 | $12K | |
| 41010 | <1% | 27 | $12K | |
| 86003 | <1% | 231 | $12K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 711 | $11K |
| 82607 | <1% | 936 | $11K | |
| 92012 | Ophthalmological services: medical examination and evaluation, intermediate, established patient | <1% | 95 | $11K |
| 85027 | <1% | 3,509 | $11K | |
| 87070 | <1% | 4,062 | $11K | |
| 87522 | Neg quan hep c or qual rna | <1% | 245 | $10K |
| 88342 | <1% | 238 | $10K | |
| 92552 | <1% | 369 | $10K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 6,101 | $10K |
| 54161 | <1% | 12 | $10K | |
| 86769 | <1% | 398 | $9K | |
| 83970 | <1% | 215 | $9K | |
| 86141 | <1% | 2,058 | $9K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 3,575 | $9K |
| 97010 | <1% | 415 | $8K | |
| 81001 | <1% | 7,654 | $8K | |
| 87077 | <1% | 1,428 | $8K | |
| 97803 | <1% | 685 | $8K | |
| 92555 | <1% | 367 | $8K | |
| 90686 | <1% | 246 | $7K | |
| 87480 | <1% | 996 | $7K | |
| 87510 | <1% | 996 | $7K | |
| 82746 | <1% | 650 | $7K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 83 | $7K |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 179 | $6K |
| 69210 | <1% | 54 | $6K | |
| 82728 | <1% | 607 | $6K | |
| 76536 | <1% | 126 | $6K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 178 | $6K |
| 87660 | <1% | 1,075 | $6K | |
| 90688 | <1% | 206 | $6K | |
| 87088 | <1% | 1,353 | $6K | |
| 59430 | <1% | 290 | $6K | |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | <1% | 227 | $6K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 103 | $6K |
| 85610 | <1% | 3,132 | $5K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 24 | $5K |
| 88307 | <1% | 70 | $5K | |
| 94010 | <1% | 218 | $5K | |
| 83001 | <1% | 321 | $5K | |
| 12002 | <1% | 12 | $5K | |
| 87186 | <1% | 1,473 | $5K | |
| 82570 | <1% | 1,365 | $5K | |
| 84146 | <1% | 295 | $5K | |
| 84702 | <1% | 912 | $4K | |
| 82784 | <1% | 378 | $4K | |
| 86803 | <1% | 2,184 | $4K | |
| 82043 | <1% | 818 | $4K | |
| 86762 | <1% | 874 | $4K | |
| 85730 | <1% | 1,938 | $4K | |
| 83735 | <1% | 2,400 | $4K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 33 | $4K |
| 93017 | <1% | 179 | $3K | |
| 83002 | <1% | 216 | $3K | |
| 97802 | <1% | 458 | $3K | |
| 87340 | <1% | 1,317 | $3K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 92 | $3K |
| 85651 | <1% | 1,881 | $3K | |
| 81002 | <1% | 7,946 | $3K | |
| 72141 | <1% | 12 | $3K | |
| 83540 | <1% | 667 | $3K | |
| 84100 | <1% | 955 | $2K | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 68 | $2K |
| 99406 | <1% | 106 | $2K | |
| 84436 | <1% | 529 | $2K | |
| 36416 | <1% | 84 | $2K | |
| 84402 | <1% | 102 | $2K | |
| 83550 | <1% | 556 | $2K | |
| 96113 | <1% | 32 | $2K | |
| 99422 | <1% | 17 | $2K | |
| 80076 | <1% | 242 | $2K | |
| 92004 | Ophthalmological services: medical examination and evaluation, comprehensive, new patient | <1% | 15 | $2K |
| 99423 | <1% | 17 | $2K | |
| 85018 | <1% | 873 | $2K | |
| 97116 | <1% | 75 | $2K | |
| 84703 | <1% | 964 | $2K | |
| 82627 | <1% | 86 | $2K | |
| D1120 | Dental cleaning, child | <1% | 32 | $2K |
| 86376 | <1% | 119 | $2K | |
| 86038 | <1% | 338 | $2K | |
| 84550 | <1% | 485 | $1K | |
| 82785 | <1% | 119 | $1K | |
| 82550 | <1% | 542 | $1K | |
| 86696 | <1% | 145 | $1K | |
| 70498 | <1% | 52 | $1K | |
| 94060 | <1% | 66 | $1K | |
| 80320 | <1% | 606 | $1K | |
| 92588 | <1% | 24 | $1K | |
| 82670 | <1% | 43 | $1K | |
| 74018 | <1% | 1,059 | $1K | |
| 86787 | <1% | 614 | $1K | |
| 86706 | <1% | 196 | $1K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 14 | $1K |
| 83690 | <1% | 2,594 | $979.63 | |
| 84154 | <1% | 49 | $970.59 | |
| 92585 | <1% | 14 | $970.08 | |
| 84156 | <1% | 635 | $938.82 | |
| 86800 | <1% | 82 | $907.36 | |
| 97166 | <1% | 12 | $899.68 | |
| 83615 | <1% | 554 | $863.57 | |
| 83020 | <1% | 391 | $861.98 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 2,041 | $861.47 |
| 88142 | <1% | 33 | $856.69 | |
| 73630 | <1% | 723 | $793.34 | |
| 86039 | <1% | 176 | $771.22 | |
| 82105 | <1% | 406 | $757.92 | |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 12 | $750.88 |
| 82977 | <1% | 197 | $748.55 | |
| 73610 | <1% | 737 | $741.47 | |
| 81003 | <1% | 714 | $738.13 | |
| 82150 | <1% | 299 | $721.74 | |
| 73564 | <1% | 352 | $697.28 | |
| 73030 | <1% | 427 | $656.58 | |
| 86431 | <1% | 146 | $641.22 | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 219 | $600.39 |
| 84480 | <1% | 127 | $598.15 | |
| 76800 | <1% | 13 | $592.80 | |
| 84134 | <1% | 100 | $583.81 | |
| 92652 | <1% | 25 | $511.66 | |
| 85032 | <1% | 639 | $490.14 | |
| 76885 | <1% | 13 | $485.10 | |
| 88312 | <1% | 14 | $484.40 | |
| 87184 | <1% | 241 | $463.26 | |
| 72100 | <1% | 146 | $452.88 | |
| 88313 | <1% | 261 | $412.80 | |
| 82565 | <1% | 212 | $403.85 | |
| 73100 | <1% | 282 | $398.65 | |
| 72040 | <1% | 163 | $393.42 | |
| Q9958 | High osmolar contrast material, up to 149 mg/ml iodine concentration, per ml | <1% | 87 | $391.68 |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 47 | $381.28 |
| 83516 | <1% | 46 | $362.64 | |
| 84484 | <1% | 3,131 | $356.93 | |
| 73590 | <1% | 418 | $356.76 | |
| 74019 | <1% | 492 | $336.06 | |
| 84460 | <1% | 74 | $334.68 | |
| 73090 | <1% | 429 | $304.48 | |
| 86765 | <1% | 27 | $303.51 | |
| 72170 | <1% | 272 | $279.36 | |
| 73130 | <1% | 499 | $278.85 | |
| 86256 | <1% | 48 | $266.75 | |
| 86235 | <1% | 14 | $259.18 | |
| 85379 | <1% | 457 | $258.41 | |
| 80348 | <1% | 59 | $254.20 | |
| 73502 | <1% | 123 | $233.35 | |
| 82803 | <1% | 723 | $229.37 | |
| 72082 | <1% | 158 | $225.41 | |
| 87075 | <1% | 43 | $223.88 | |
| 87040 | <1% | 740 | $221.20 | |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | <1% | 587 | $220.95 |
| 85045 | <1% | 145 | $218.01 | |
| 73070 | <1% | 363 | $212.64 | |
| 80361 | <1% | 30 | $211.66 | |
| 0012A | <1% | 13 | $204.00 | |
| 82248 | <1% | 63 | $202.73 | |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 14 | $200.20 |
| 74240 | <1% | 12 | $198.00 | |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 15 | $196.32 |
| 73562 | <1% | 88 | $189.00 | |
| 83605 | <1% | 1,099 | $185.06 | |
| 71045 | Radiologic examination, chest; single view | <1% | 2,463 | $164.79 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 898 | $163.59 |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | <1% | 124 | $159.90 |
| 82533 | <1% | 12 | $159.54 | |
| 87147 | <1% | 903 | $143.00 | |
| 82103 | <1% | 14 | $141.25 | |
| 88302 | <1% | 64 | $133.14 | |
| 72110 | <1% | 40 | $126.00 | |
| 83525 | <1% | 13 | $125.12 | |
| 73110 | <1% | 348 | $120.75 | |
| 87116 | <1% | 13 | $120.06 | |
| 82947 | <1% | 119 | $116.63 | |
| 87181 | <1% | 23 | $112.50 | |
| 86225 | <1% | 27 | $111.30 | |
| 82948 | <1% | 2,420 | $111.07 | |
| 86255 | <1% | 16 | $104.24 | |
| 77072 | <1% | 12 | $100.98 | |
| 86160 | <1% | 13 | $99.61 | |
| 86735 | <1% | 13 | $96.36 | |
| 82330 | <1% | 59 | $92.13 | |
| 73552 | <1% | 90 | $90.70 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,235 | $85.20 |
| 80177 | <1% | 27 | $82.84 | |
| 84450 | <1% | 17 | $82.08 | |
| 87101 | <1% | 27 | $80.27 | |
| 86580 | <1% | 16 | $80.00 | |
| 77073 | <1% | 117 | $77.68 | |
| 84132 | <1% | 89 | $73.81 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 827 | $63.56 |
| 89060 | <1% | 17 | $62.46 | |
| 76377 | <1% | 335 | $60.00 | |
| 86709 | <1% | 14 | $60.00 | |
| 86708 | <1% | 14 | $60.00 | |
| 76870 | <1% | 95 | $55.08 | |
| 74022 | <1% | 81 | $47.42 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 121 | $45.10 |
| 73560 | <1% | 51 | $36.36 | |
| 85014 | <1% | 150 | $36.36 | |
| 87210 | <1% | 498 | $36.25 | |
| 94760 | <1% | 444 | $33.86 | |
| 85004 | <1% | 25 | $31.70 | |
| 73060 | <1% | 35 | $30.34 | |
| 94664 | <1% | 29 | $30.06 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 4,175 | $28.71 |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | <1% | 13 | $24.49 |
| 76857 | <1% | 12 | $24.48 | |
| 86317 | <1% | 12 | $23.74 | |
| 83874 | <1% | 2,328 | $21.50 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,150 | $17.52 |
| 87081 | <1% | 16 | $15.60 | |
| 87015 | <1% | 12 | $14.58 | |
| 89051 | <1% | 15 | $11.20 | |
| J2704 | Injection, propofol, 10 mg | <1% | 2,924 | $11.18 |
| 86308 | <1% | 52 | $9.55 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 123 | $5.75 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 454 | $4.92 |
| 84295 | <1% | 38 | $4.91 | |
| 85007 | <1% | 18 | $2.86 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 88 | $2.32 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,083 | $1.86 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,976 | $1.72 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 106 | $0.60 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,235 | $0.41 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 75 | $0.39 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 88 | $0.00 |
| 96375 | Therapeutic injection; each additional sequential IV push | 0% | 2,989 | $0.00 |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 644 | $0.00 |
| 88300 | 0% | 482 | $0.00 | |
| 96127 | 0% | 391 | $0.00 | |
| 96376 | 0% | 739 | $0.00 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 396 | $0.00 |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 0% | 4,961 | $0.00 |
| C1769 | Guide wire | 0% | 568 | $0.00 |
| 80329 | 0% | 208 | $0.00 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 0% | 3,775 | $0.00 |
| 87430 | 0% | 237 | $0.00 | |
| 99417 | Prolong home eval add 15m | 0% | 151 | $0.00 |
| J3480 | Injection, potassium chloride, per 2 meq | 0% | 316 | $0.00 |
| S2900 | Surgical techniques requiring use of robotic surgical system (list separately in addition to code for primary procedure) | 0% | 37 | $0.00 |
| 86710 | 0% | 2,146 | $0.00 | |
| 87451 | 0% | 25 | $0.00 | |
| J2060 | Injection, lorazepam, 2 mg | 0% | 150 | $0.00 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 85 | $0.00 |
| Q9969 | Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose | 0% | 24 | $0.00 |
| 82677 | 0% | 13 | $0.00 | |
| 94761 | 0% | 14 | $0.00 | |
| 87625 | 0% | 12 | $0.00 | |
| 81050 | 0% | 12 | $0.00 | |
| J1644 | Injection, heparin sodium, per 1000 units | 0% | 579 | $0.00 |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 146 | $0.00 |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 45 | $0.00 |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 2,154 | $0.00 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 342 | $0.00 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | 0% | 670 | $0.00 |
| 83721 | 0% | 330 | $0.00 | |
| 87420 | 0% | 1,185 | $0.00 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 625 | $0.00 |
| A0100 | Non-emergency taxi ride to a medical appointment | 0% | 317 | $0.00 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 97 | $0.00 |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 0% | 96 | $0.00 |
| S0215 | Non-emergency transportation; mileage, per mile | 0% | 317 | $0.00 |
| 90472 | Immunization administration, each additional vaccine (list separately) | 0% | 46 | $0.00 |
| 99354 | 0% | 83 | $0.00 | |
| 87400 | 0% | 2,568 | $0.00 | |
| 82010 | 0% | 133 | $0.00 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 67 | $0.00 |
| J0694 | Injection, cefoxitin sodium, 1 gm | 0% | 16 | $0.00 |
| 86336 | 0% | 13 | $0.00 | |
| 92610 | 0% | 16 | $0.00 | |
| 73140 | 0% | 26 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialPUCCIO, JOANNE (CRENTIALING AR RECEIVABLES MANAGER)